Technology
Health
Biotechnology

Innovate Biopharmaceuticals

$1.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.52%) Today
-$0.01 (-0.52%) Today

Why Robinhood?

You can buy or sell INNT and other stocks, options, ETFs, and crypto commission-free!

About

Innovate Biopharmaceuticals, Inc. Common Stock, also called Innovate Biopharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It foucs on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

Employees
8
Headquarters
Raleigh, North Carolina
Founded
2012
Market Cap
50.09M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
498.76K
High Today
$2.20
Low Today
$1.90
Open Price
$1.97
Volume
649.96K
52 Week High
$50.50
52 Week Low
$1.70

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2016 IPO
US

News

Seeking AlphaMar 4

Innovate Biopharmaceuticals (INNT) Presnts At Conference Call to Provide Corporate and Operational Updates - Slideshow

The following slide deck was published by Innovate Biopharmaceuticals, Inc. in conjunction with this event. 1 32 Click to enlarge Notes:...

881
MarketBeatFeb 23

Stock Price, News, & Analysis for Innovate Biopharmaceuticals

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease. In addition, the...

195
Simply Wall StFeb 16

Do Directors Own Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) Shares?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! A look at the shareholders of Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, β€˜Don’t tell me wh...

35

Earnings

-$1.38
-$0.93
-$0.48
-$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
β€”
Actual
-$0.11 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.